Back to Sectors

ESTA

ESTABLISHMENT LABS HOLDINGS INC.
13 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

BULLISH | 90% | 5/8/2026 | earnings beatBULLISH | 70% | 5/8/2026 | margin expansionBULLISH | 80% | 5/8/2026 | debt restructureBEARISH | 60% | 5/8/2026 | margin compressionBULLISH | 90% | 5/8/2026 | earnings beatBULLISH | 70% | 5/8/2026 | margin expansionBULLISH | 80% | 5/8/2026 | debt restructureBEARISH | 60% | 5/8/2026 | margin compressionBULLISH | 90% | 5/8/2026 | earnings beatBULLISH | 70% | 5/8/2026 | margin expansionBULLISH | 80% | 5/8/2026 | debt restructureBEARISH | 60% | 5/8/2026 | margin compressionBULLISH | 90% | 5/8/2026 | earnings beatBULLISH | 70% | 5/8/2026 | margin expansionBULLISH | 80% | 5/8/2026 | debt restructureBEARISH | 60% | 5/8/2026 | margin compressionBULLISH | 90% | 5/8/2026 | earnings beatBULLISH | 70% | 5/8/2026 | margin expansionBULLISH | 80% | 5/8/2026 | debt restructureBEARISH | 60% | 5/8/2026 | margin compressionBULLISH | 90% | 5/8/2026 | earnings beatBULLISH | 70% | 5/8/2026 | margin expansionBULLISH | 80% | 5/8/2026 | debt restructureBEARISH | 60% | 5/8/2026 | margin compressionBULLISH | 90% | 5/8/2026 | earnings beatBULLISH | 70% | 5/8/2026 | margin expansionBULLISH | 80% | 5/8/2026 | debt restructureBEARISH | 60% | 5/8/2026 | margin compressionNEUTRAL | 30% | 5/22/2026 | management changeBULLISH | 50% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeBULLISH | 50% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeBULLISH | 50% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeBULLISH | 50% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeBULLISH | 50% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeBULLISH | 50% | 5/22/2026 | regulatory actionMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

neutralMay 22

Board of directors re-elected with majority support but notable pockets of dissent.

management change
30%
bullishMay 22

Successful ratification of independent auditor and executive compensation.

regulatory action
50%
neutralMay 22

Board of directors re-elected with majority support but notable pockets of dissent.

management change
30%
bullishMay 22

Successful ratification of independent auditor and executive compensation.

regulatory action
50%
neutralMay 22

Board of directors re-elected with majority support but notable pockets of dissent.

management change
30%
bullishMay 22

Successful ratification of independent auditor and executive compensation.

regulatory action
50%
neutralMay 22

Board of directors re-elected with majority support but notable pockets of dissent.

management change
30%
bullishMay 22

Successful ratification of independent auditor and executive compensation.

regulatory action
50%
neutralMay 22

Board of directors re-elected with majority support but notable pockets of dissent.

management change
30%
bullishMay 22

Successful ratification of independent auditor and executive compensation.

regulatory action
50%
neutralMay 22

Board of directors re-elected with majority support but notable pockets of dissent.

management change
30%
bullishMay 22

Successful ratification of independent auditor and executive compensation.

regulatory action
50%
bullishMay 8

Revenue grew 44.7% YoY driven by successful U.S. market penetration.

earnings beat
90%
bullishMay 8

Gross margin increased to 70.7% due to higher U.S. pricing.

margin expansion
70%
bullishMay 8

Refinanced debt via a new $300M credit agreement extending maturity to 2031.

debt restructure
80%
bearishMay 8

SG&A expenses continue to exceed gross profit, preventing operational profitability.

margin compression
60%
bullishMay 8

Revenue grew 44.7% YoY driven by successful U.S. market penetration.

earnings beat
90%
bullishMay 8

Gross margin increased to 70.7% due to higher U.S. pricing.

margin expansion
70%
bullishMay 8

Refinanced debt via a new $300M credit agreement extending maturity to 2031.

debt restructure
80%
bearishMay 8

SG&A expenses continue to exceed gross profit, preventing operational profitability.

margin compression
60%
bullishMay 8

Revenue grew 44.7% YoY driven by successful U.S. market penetration.

earnings beat
90%
bullishMay 8

Gross margin increased to 70.7% due to higher U.S. pricing.

margin expansion
70%
bullishMay 8

Refinanced debt via a new $300M credit agreement extending maturity to 2031.

debt restructure
80%
bearishMay 8

SG&A expenses continue to exceed gross profit, preventing operational profitability.

margin compression
60%
bullishMay 8

Revenue grew 44.7% YoY driven by successful U.S. market penetration.

earnings beat
90%
bullishMay 8

Gross margin increased to 70.7% due to higher U.S. pricing.

margin expansion
70%
bullishMay 8

Refinanced debt via a new $300M credit agreement extending maturity to 2031.

debt restructure
80%
bearishMay 8

SG&A expenses continue to exceed gross profit, preventing operational profitability.

margin compression
60%
bullishMay 8

Revenue grew 44.7% YoY driven by successful U.S. market penetration.

earnings beat
90%
bullishMay 8

Gross margin increased to 70.7% due to higher U.S. pricing.

margin expansion
70%
bullishMay 8

Refinanced debt via a new $300M credit agreement extending maturity to 2031.

debt restructure
80%
bearishMay 8

SG&A expenses continue to exceed gross profit, preventing operational profitability.

margin compression
60%
bullishMay 8

Revenue grew 44.7% YoY driven by successful U.S. market penetration.

earnings beat
90%
bullishMay 8

Gross margin increased to 70.7% due to higher U.S. pricing.

margin expansion
70%
bullishMay 8

Refinanced debt via a new $300M credit agreement extending maturity to 2031.

debt restructure
80%
bearishMay 8

SG&A expenses continue to exceed gross profit, preventing operational profitability.

margin compression
60%
bullishMay 8

Revenue grew 44.7% YoY driven by successful U.S. market penetration.

earnings beat
90%
bullishMay 8

Gross margin increased to 70.7% due to higher U.S. pricing.

margin expansion
70%
bullishMay 8

Refinanced debt via a new $300M credit agreement extending maturity to 2031.

debt restructure
80%
bearishMay 8

SG&A expenses continue to exceed gross profit, preventing operational profitability.

margin compression
60%

Filing History

8-KMay 22, 2026

The 8-K filing confirms that Establishment Labs has maintained its leadership structure and ratified its accounting firm, providing a baseline of operational continuity. While the company presents this as a victory for governance stability, the underlying voting friction suggests a divide between the company's narrative and a subset of its shareholders. Investors must now weigh the benefit of a stable board against the risks highlighted by dissenting votes and the company's upcoming financial obligations.

10-QMay 8, 2026

The Q1 2026 filing presents a company at a crossroads between explosive growth and structural instability. The successful U.S. launch has provided a massive revenue catalyst and improved the immediate outlook for top-line scaling. However, the underlying financials reveal a business that is still heavily reliant on debt and struggling to reach a point where gross profits can cover the high costs of sales and administration. The recent refinancing of the Oaktree debt is a critical lifeline that prevents a near-term liquidity crisis and provides the necessary breathing room to execute the U.S. strategy. Investors must now weigh the impressive 44.7% revenue growth against the persistent operating losses and the risks associated with a single-source supply chain. The ultimate success of the thesis depends on whether the company can translate its U.S. market share gains into a sustainable, cash-flow-positive operating model before its debt obligations become an insurmountable burden.